Cost of non-small cell lung cancer in Italy. Results of the longitudinal study ALCEA (Advanced Lung Cancer Economic Assessment).

@article{Perrone2004CostON,
  title={Cost of non-small cell lung cancer in Italy. Results of the longitudinal study ALCEA (Advanced Lung Cancer Economic Assessment).},
  author={Francesco Perrone and Giancarlo Benelli and Stefania Lopatriello and Luigi Portalone and Franco Salvati and Pier Luigi Zorat and Cristina Negrini},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 14_suppl},
  pages={8265}
}
8265 Background: Lung cancer is extremely common and its cost for society is not extensively studied. ALCEA (Advanced Lung Cancer Economic Assessment) -an observational cost-of-illness study -has generated economic data on patients affected by NSCLC in an advanced stage, exploring both direct and indirect costs determined by this pathology in Italy. METHODS A total of 189 patients treated with first line chemotherapy (1st L), second line chemotherapy (2nd L) or supportive therapy (ST) were… CONTINUE READING